Patient Safety Movement Foundation Announces Winners of 2020 Humanitarian Awards
10.2.2021 16:00:00 EET | Business Wire | Press release
The Patient Safety Movement Foundation (PSMF), a global non-profit committed to achieving zero preventable patient deaths by 2030, announced the winners of its 2020 Humanitarian Awards at a virtual ceremony on February 8, 2021. The recipients included Steve Burrows, Vonda Vaden Bates, Marty Hatlie and Barb Pelletreau. Each year the Humanitarian Awards recognize leaders who have made significant progress in the last year eliminating or raising awareness of preventable patient deaths.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210210005339/en/
Steve Burrows, Vonda Vaden Bates, Marty Hatlie and Barb Pelletreau were recognized by the Patient Safety Movement Foundation for their efforts eliminating and raising awareness of preventable patient deaths (Photo: Business Wire)
“To achieve our goal of zero preventable patient deaths by 2030, it is critical to unify people and collectively improve patient safety across the globe,” said David B. Mayer, MD, CEO of Patient Safety Movement Foundation. “We are pleased to honor each of these individuals for their remarkable efforts to spread public awareness of this important issue and improve the patient experience for everyone.”
The Humanitarian Award recipients were honored across three categories this year – the Judie Burrows award, Michael Seres award and Steven Moreau award. The Judie Burrows award was established to recognize an individual who has told a story of preventable harm or death that has made a significant impact in the public sphere in the last year. The Michael Seres award was designed in honor of lifelong patient safety advocate, Michael Seres, who passed away in May 2020. This award recognizes an individual who contributed to the advancement of person and family engagement, public awareness and public engagement in patient safety. The Steven Moreau award is given to a hospital administrator who possesses a zeal for improving patient safety at their hospital. This year’s recipients included:
- Steve Burrows, writer and director of the acclaimed documentary “Bleed Out,” was recognized with the Judie Burrows award for the impact his HBO film had in elevating the issues around patient safety in the public domain. His documentary follows the story of his mother, Judie Burrows, who experienced a preventable medical error during a partial hip surgery that afflicted her for the rest of her life. Since “Bleed Out” was released in December 2018 over 10 million viewers have watched the film on HBO. Prior to its release, Burrows, his wife Margo and their family thought they were alone, but within the first 24 hours of the film streaming they were inundated with thousands of Facebook messages from strangers who connected with Judie Burrows’ story.
- Vonda Vaden Bates has been passionate about advancing public awareness and engagement around the issue of preventable hospital deaths since losing her husband, Charles “Yogiraj” Bates II, to a preventable venous thromboembolism in 2012. She played an integral role in the conceptualization and success of the #uniteforsafecare campaign – a collaborative effort between the Patient Safety Movement Foundation, American Society of Anesthesiologists (ASA), The Leapfrog Group and International Society for Quality in Health Care (ISQua) to bring attention to system-wide improvements that will ensure better health worker and patient safety outcomes. Bates was recognized with the Michael Seres award for her efforts to advance public awareness and for helping make the #uniteforsafecare campaign and PSMF-hosted events in September 2020 a success.
- Marty Hatlie was also honored with the Michael Seres award. Hatlie has been a lifelong leader in patient safety since he served as executive director of the National Patient Safety Foundation. However, this humanitarian award acknowledges his exemplary work in the last 12 months. Hatlie served as one of the co-chairs for the March for Patient Safety turned #uniteforsafecare campaign. He dedicated much of 2019 and 2020 to launching the initiative.
- Barb Pelletreau, senior vice president of patient safety at CommonSpirit Health (formally known as Dignity Health), received the Steven Moreau award. Pelletreau was recognized for her leadership of the now 150+ hospital system, where she leads patient safety improvement efforts with transparency and candor. Under her leadership, Dignity Health became a PSMF 5-star hospital for making commitments in alignment with the Patient Safety Movement Foundation’s evidence-based Actionable Patient Safety Solutions (APSS) last year, reaffirming its dedication and commitment to zero preventable deaths.
The Patient Safety Movement Foundation launched the Humanitarian Awards in 2013 to recognize individuals whose work helps advance patient safety. To learn more about the awards and past winners, visit: https://patientsafetymovement.org.
To watch the award presentation, visit https://patient.sm/Humanitarian-Awards.
About the Patient Safety Movement Foundation: Each year, more than 200,000 people die unnecessarily in U.S. hospitals. Worldwide, 4.8 million lives are similarly lost. The Patient Safety Movement Foundation (PSMF) is a global non-profit on a mission to eliminate preventable deaths from hospital errors. PSMF uniquely brings patients and patient advocates, healthcare providers, medical technology companies, government, employers and private payers together under the same cause. From its Actionable Patient Safety Solutions and industry Open Data Pledge to its World Patient Safety, Science & Technology Summit and more, PSMF won’t stop fighting until it achieves zero. For more information, please visit patientsafetymovement.org to learn more, and follow PSMF on LinkedIn, Twitter, Instagram and Facebook.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210210005339/en/
Contact information
Leslie Licano, Beyond Fifteen Communications, Inc.
psmf@beyondfifteen.com | (949) 733-8679 ext.101
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
